Nota de idioma: o chrome desta página está em português; o corpo longo abaixo permanece em inglês para preservar a precisão das fontes.
CJC-1295
Also indexed as CJC1295 · DAC-GRF · long-acting GHRH analog
CJC-1295 is a synthetic long-acting analog of GHRH studied in healthy adults and endocrine pharmacology. The human papers describe hormone responses under research protocols, not an approved product pathway.
Last reviewed 2026-09-07 · education only
O que aparece na literatura
The analog was designed to extend GHRH-like signaling, including through albumin binding described in the literature. That pharmacokinetic idea does not supply dosing or clinical guidance.
History & development
- 2006
Two Journal of Clinical Endocrinology & Metabolism papers reported prolonged GH/IGF-1 stimulation and preserved pulsatility in healthy adults.
Source: CJC-1295 human trial ↗
Approved brands & pathway
CJC-1295 is presented for research-name and evidence literacy. A research name does not authenticate a product or establish a human-use pathway.
Entradas de evidência
Nenhuma entrada está vinculada a este perfil.
Grade mix in this atlas
Grades describe the cited record for a narrow question. They do not score a marketplace material or make a health decision.
No evidence entries are mapped to this profile yet.
Naming curiosities & useful distinctions
- DAC refers to the drug-affinity complex strategy described for the analog; it is not a brand.
- CJC-1295 and GHRH are related by design but are not interchangeable names.
A pharmacology paper, not a product label
The 2006 study is useful for understanding half-life and hormone-response questions. It does not establish approval, long-term safety or the identity of a marketplace material.
Nomes no registro
Clinical study authors
Sam L. Teichman and colleagues
The cited papers report human pharmacology of CJC-1295; they are not evidence of an approved consumer product.